Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies-Reference-Cited by-同舟云学术

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Published:2012-07 Issue:7 Volume:18 Page:1128-1135
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Hamadani Mehdi,Kochuparambil S. Thomas,Osman Salman,Cumpston Aaron,Leadmon Sonia,Bunner Pamela,Watkins Kathy,Morrison Devi,Speir Ethan,DeRemer David,Kota Vamsi,Jillella Anand,Craig Michael,Awan Farrukh

Funder

Conquer Cancer Foundation of American Society of Clinical Oncology Career Development Award

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference24 articles.

1. Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;N Engl J Med,1996

2. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

3. Improving stem cell mobilization strategies: future directions;Bensinger;Bone Marrow Transplant,2009

4. Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy;Wood;Biol Blood Marrow Transplant,2011

5. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens;Kumar;Blood,2009

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience;Annals of Medicine;2023-12-12

2. A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents;Haematologica;2023-11-16

3. Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma;Haematologica;2023-07-13

4. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma;Transfusion and Apheresis Science;2023-06

5. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments;Annals of Hematology;2023-03-22